Mitomycin-C 30 mg for 12 months versus Mitomycin-C 40 mg for 6 months in the prophylaxis of superficial bladder carcinoma G1-G2;Mitomycin-C 30 mg per 12 mesi versus Mitomycin-C 40 mg per 6 mesi nella profilassi del carcinoma superficiale della vescica G1-G2

Minerva Urologica e Nefrologica

Volumn 48, Issue 4, 1996, Pages 203-206

  Vecchioli Scaldazza, C ^a,b  

^a Ospedale Civile Di Vicenza   (Italy)

^b NONE   (Italy)

Author keywords

bladder neoplasms; chemotherapy; transitional cell carcinoma

Indexed keywords

MITOMYCIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TRANSITIONAL CELL CARCINOMA;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, TRANSITIONAL CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 0029802247     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Torti FM, Lum BL. The biology and treatment of superficial bladder cancer. J Clin Oncol 1984,2.531-50.
2. Torti FM, Lum BL Superficial carcinoma of the bladder natural history and the rule of interferons. Semin Oncol 1986;13:57-60.
3. Cutler SJ, Heney NM, Friedell GHL. Longitudinal study of patients with disease recurrence and progression. In: Bonner WW, Prout GR Jr, editors. Monographs: bladder cancer. Baltimore AVA, 1982: 35-46
4. Shida K. Treatment of the bladder cancer with instillations of Mitomicin C (first report). Jpn Clin Urol 1967;21:1075.
5. Ausfeld R, Beer M, Muhlethaler JP et al. Adjuvant intravesical chemotherapy of superficial bladder cancer with monthly Doxyrubicin or intensive Mitomycin. Eur Urol 1987;13:10-4
6. Denovec M, Bouvier R, Sarkissian J et al Intravesical instillation of Mitomycin C in the prophylactic treatment of recurring superficial transitional cell carcinoma of the bladder Br J Urol 1983;55:382-5.
7. Engelmann U, Frohneberg D, Jakse G et al Die intravesikale rezidiv Chemoprophylaxe des Oberflachlichen Harnblasentumors In Intravesikale chemotherapie und transurethrale Verfahren zur Behandlung und Rezidivprophylaxe des blasenkarzinoms In: Hallwacks O, Altwein JE, editors Darmstadt: Steinhopff Verlag. 1982:32-5.
8. Flanigan RC, Ellison MF, Butler KM et al. A trial of prophylactic thiotepa or Mitomicin C intravesical therapy in patients with recurrent or multiple superficial bladder cancer. J Urol 1986;136:35-7.
9. Fluchter SH, Harzmann R, Bichler KH Local Mitomycin C therapy of transitional cell carcinoma of the bladder-serum resorption study and clinical results. In. Ogawa M, Rozencweig M, Staquet MJ, editors. Mitomycin C, current impact oc cancer chemotherapy. Amsterdam: Excerpta Medica, 1982:143-52
10. Huland H, Otto U Use of Mitomycin as prophylaxis following endoscopic resection of superficial bladder cancer. Urology 1985;26(Suppl):32-5.
11. Zincke H, Benson RC, Hilton JF et al Intravesical thiotepa and Mitomycin C treatment immediately after transurethral resection and later for superficial (stage Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design J Urol 1985,134:1110-3.
12. Giesbers GM, Van Hisdingen RO, Kramer JL. Recurrence of superficial carcinoma after intravesical instillation of Mitomycin C Comparison of exposure times Br J Urol 1989,63:176-9
13. Pagano F, Guazzieri S, Garbeglio A et al. Mitomycin C, Adriamycin and Bacillus of Calmette Guerin as adjuvant topic therapy in superficial transitional cell carcinoma In: Di Silverio F, Steg A, editors. New trends in bladder cancer chemotherapy Roma. Acta Medica Edizioni e Congressi, 1987.227-33.
14. Vecchioli Scaldazza C. La profilassi del carcinoma a cellule di transizione della vescica G1-G2; pTa-pT1 con Mitomycin C o Interferone alfa-2a. Dati preliminari Minerva Urol Nefrol 1993;45 117-21.
15. Kurth KH, Bouffioux C, Sylvester R, De Pauw M and members of the EORTC GU Group. Early and delayed instillation with and without maintenance of either Adriamycin or Mitomycm-C in patients with superficial transitional carcinoma of the bladder. In. Di Silverio F, Steg A, editors New trends in bladder cancer chemotherapy. Roma: Acta Medica Edizioni e Congressi, 1987 159-64
16. Huland H, Kloppel G, Otto U et al Cytostatic intravesical instillation in patients with superficial bladder carcinoma for prevention of recurrent tumors. In. Di Silverio F, Steg A, editors. New trends in bladder cancer chemotherapy. Roma: Acta Medica Edizioni e Congressi, 1987.147-58